Nilotinib Stada (Nilotinib)

Nilotinib works by selectively binding to the ATP‑binding site of the BCR‑ABL tyrosine kinase, blocking its activity. This inhibition stops downstream signaling that promotes proliferation and survival of leukemic cells, leading to apoptosis of the malignant clone while sparing most normal cells.

The dosage of Nilotinib is individualized and set by the prescribing physician based on the patient’s disease phase, body weight, renal and hepatic function, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Nilotinib during pregnancy and lactation has not been established. The drug is classified as contraindicated for use in pregnant or nursing women unless the potential benefit justifies the risk. Effective contraception is recommended for women of child‑bearing potential.

To order Nilotinib Stada, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Nilotinib is imatinib, another BCR‑ABL tyrosine kinase inhibitor. Nilotinib is generally more potent and may achieve faster and deeper molecular responses, but it also carries a higher risk of QT prolongation and metabolic disturbances. Choice of therapy depends on patient‑specific factors and physician judgment.

Nilotinib tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Nilotinib is taken orally, usually twice daily on an empty stomach (at least one hour before or two hours after a meal). The tablets should be swallowed whole with a glass of water; they must not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious risks include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe liver toxicity, pancreatitis, and marked reductions in blood cell counts (neutropenia, thrombocytopenia). Patients should be monitored regularly with ECGs, liver function tests, and complete blood counts.

Nilotinib should not be used by patients with a known hypersensitivity to the drug, those with a prolonged QT interval, uncontrolled cardiac disease, or severe hepatic impairment. It is also contraindicated in pregnant or nursing women unless the benefits outweigh the risks.